EU Hesitates on Approving Alzheimer’s Drugs: The Donanemab Story The European Union remains cautious regarding the approval of new Alzheimer’s drugs. Donanemab, a drug showing promise in slowing Alzheimer’s progression, has been approved in the US, Japan, China, and the United Kingdom. However, the European Medicines Agency (EMA) has not yet granted its approval for […]
Source link